Evidence map›Paper›PMID 38139455›Full record

ArticleInternational journal of molecular sciences2023

Single-Nucleotide Polymorphisms of the

Moe Soeda, Seii Ohka, Daisuke Nishizawa, Masako Iseki, Keisuke Yamaguchi, Hideko Arita, Kazuo Hanaoka, Jitsu Kato, Setsuro Ogawa, Ayako Hiranuma and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 4 citations in OpenAlex.

  1. Dopamine transporter gene (Pain reports · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 1 country.

Moe SoedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Seii OhkaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0000-0003-2394-6440
Daisuke NishizawaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0000-0001-8286-4651
Masako IsekiDepartment of Anesthesiology & Pain Medicine, Juntendo University School of Medicine, Tokyo 113-8431, Japan.
Keisuke YamaguchiDepartment of Anesthesiology & Pain Medicine, Juntendo University School of Medicine, Tokyo 113-8431, Japan.ORCID 0000-0001-6209-715X
Hideko AritaDepartment of Anesthesiology, Pain Relief Center, JR Tokyo General Hospital, Tokyo 151-8528, Japan.
Kazuo HanaokaDepartment of Anesthesiology, Pain Relief Center, JR Tokyo General Hospital, Tokyo 151-8528, Japan.
Jitsu KatoDepartment of Anesthesiology, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Setsuro OgawaUniversity Research Center, Nihon University, Tokyo 173-8610, Japan.
Ayako HiranumaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Junko HasegawaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Kyoko NakayamaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Yuko EbataAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Masakazu HayashidaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.
Tatsuya IchinoheDepartment of Dental Anesthesiology, Tokyo Dental College, Tokyo 101-0061, Japan.
Ken-Ichi FukudaDepartment of Oral Health and Clinical Science, Tokyo Dental College, Tokyo 101-0061, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan.ORCID 0000-0001-8342-0278
Tokyo Metropolitan Institute of Medical Science · JPJuntendo University · JPTokyo Dental College · JPJR Tokyo General Hospital · JPNihon University · JPToho University · JP

Funding

Japan Agency for Medical Research and Development JP19ek0610011Japan Society for the Promotion of Science 20K07774, 17K09052, 20K09259, 17K08970, 22K10202, 21H03028, 17H04324, JP22H04922 (AdAMS)
6 · The paper itself

Abstract

Patients with chronic pain are affected psychologically and socially. There are also individual differences in treatment efficacy. Insufficient research has been conducted on genetic polymorphisms that are related to individual differences in the susceptibility to chronic pain. Autoimmune disorders can lead to inflammation and chronic pain; therefore, we focused on the autoimmune-related protease-activated receptor 2 (

Indexed as

Autoimmune DiseasesChronic PainInterleukin-17Receptor, PAR-2Case-Control StudiesGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotideF2RL1 protein, humanInterleukin-17Receptor, PAR-2astrocytechronic paininterleukin 17Aprotease-activated receptor 2T-helper 17

Identifiers

PMID38139455
PMCPMC10744199
OpenAlexW4389916352

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.